It has been found that several PI3K/Akt/mTOR targeted therapies such as pictilisib (PI3K inhibitor) and perifosine (Akt inhibitor) are undergoing clinical trials as treatments for lung cancer [5]. Here, MTOR is linked to lung cancer.